findmyKOL
Clinical trialNCT02706392TerminatedPhase 1Interventional

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

SponsorFred Hutchinson Cancer CenterEnrollment21Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Triple-Negative Breast CarcinomaRecurrent Acute Lymphoblastic LeukemiaRecurrent Mantle Cell Lymphoma+7 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Mar 2016
Primary completion
17 May 2021
Completion
28 Sept 2021
Last update posted
31 Aug 2022
Registered enrollment
21
Registry id
NCT02706392
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.